CardiologyATTR-CMRNA 干扰
Vutrisiran and Tafamidis in Transthyretin Amyloidosis Cardiomyopathy: Evaluating Combination Therapy Insights from HELIOS-B
By MedXY|Sep 1, 2026
The HELIOS-B trial showed vutrisiran improves survival and cardiac outcomes in transthyretin amyloidosis with cardiomyopathy, with consistent benefits regardless of baseline tafamidis use, supporting further evaluation of combination therap
